Jumo Health Launches PRISM System to Address Clinical Trial Patient Readiness and Retention Challenges
核心洞察
Jumo Health (搜索) has launched PRISM, a patent-pending clinical trial recruitment, enrollment, and retention system designed to address persistent failures in research by focusing on patient readiness.
The system targets challenges that arise after enrollment when medically eligible patients are not fully prepared for participation, leading to screen failures, protocol deviations, and early dropout.
PRISM operationalizes readiness as a core execution variable and uses intelligent pre-screening, decision science, and early interventions to deliver decision-ready patients to sites.
Jumo Health (搜索) has launched PRISM, a patent-pending clinical trial recruitment, enrollment, and retention system designed to tackle persistent failures in clinical research by addressing a critical gap in patient preparedness. The system specifically targets challenges that emerge after enrollment, when medically eligible patients are not always fully prepared for participation in clinical trials.
Addressing Post-Enrollment Challenges
The PRISM system addresses a significant problem in clinical research where patient eligibility alone does not guarantee successful trial participation. According to Jumo Health (搜索), inadequate patient preparation can lead to screen failure after consent, protocol deviations, site escalation, early dropout, and the need for costly rescue recruitment efforts.
PRISM aims to operationalize readiness as a core execution variable, fundamentally reframing decision-making throughout recruitment and retention based on whether participation is likely to endure under real trial conditions.
System Capabilities and Features
The PRISM platform incorporates several key functionalities designed to improve trial outcomes. The system models activation and readiness propensity, delivers decision-ready patients to sites through intelligent pre-screening and site handoff, and applies decision science to reduce decision burden on both patients and sites.
Additionally, PRISM implements early interventions to protect retention and monitors readiness across the entire trial lifecycle. The system is offered to biopharma sponsors and research collaborators within specific therapeutic fields.
Industry Leadership Perspective
Adam Cossman, chairman of Jumo Health (搜索), emphasized the company's established role in patient education. "From the beginning, Jumo Health has been the industry leader in readiness education, helping patients and their caregivers understand what clinical trial participation truly entails and make informed, confident decisions. PRISM is a natural extension of that mission," Cossman said.
He further explained that the system "takes the trust, health literacy, and expectation-setting programmes Jumo has built for hundreds of studies and operationalises it across recruitment, enrolment, and retention, so trials don't just enrol patients but are designed for patients to succeed."
Redefining Clinical Research Execution
Brittany Erana, CEO of Jumo Health (搜索), highlighted a fundamental shift in approach to clinical trial management. "Clinical trials have spent decades optimising how patients are recruited, but very little time questioning whether those patients are truly prepared to participate and complete," Erana stated.
According to Erana, "PRISM defines a new execution model for clinical research, one that treats readiness as a first-class requirement, not an afterthought. When readiness is governed, trials become more predictable, more inclusive, and far more likely to finish as planned."